Insider Selling: Natera (NASDAQ:NTRA) Director Sells $2,389,310.00 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Natera Trading Up 1.3%

Shares of NASDAQ NTRA opened at $219.23 on Friday. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36. The stock’s fifty day simple moving average is $206.32 and its two-hundred day simple moving average is $216.02. The stock has a market capitalization of $31.40 billion, a PE ratio of -134.50 and a beta of 1.56.

Institutional Investors Weigh In On Natera

Several institutional investors have recently added to or reduced their stakes in the business. Horizon Investments LLC increased its holdings in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 44 shares in the last quarter. Sound Income Strategies LLC increased its stake in Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares in the last quarter. Savvy Advisors Inc. increased its stake in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares during the last quarter. Finally, First Horizon Corp raised its holdings in shares of Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after buying an additional 51 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on NTRA shares. Piper Sandler reiterated an “overweight” rating and issued a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Robert W. Baird set a $265.00 price target on shares of Natera in a report on Friday, May 8th. Wolfe Research initiated coverage on shares of Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, William Blair assumed coverage on shares of Natera in a research report on Tuesday, April 14th. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $256.53.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.